Document Detail

Impact of timing on efficacy and safetyof intracoronary autologous bone marrow stem cells transplantation in acute myocardial infarction: a pooled subgroup analysis of randomized controlled trials.
MedLine Citation:
PMID:  19685520     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Until now there were no clinical studies or systematic reviews to investigate the impact of timing on efficacy and safety of intracoronary bone marrow stem cell (BMSC) transfer in patients with acute myocardial infarction (AMI). HYPOTHESIS: Timing of BMSC administration might play an important role in the therapeutic response in AMI patients. METHODS: A systematic literature search of PubMed, MEDLINE, and Cochrane Evidence-Based Medicine (EBM) databases was made on randomized controlled trials with at least 3-month follow-up data for patients with AMI undergoing emergent percutaneous coronary intervention (PCI) and receiving intracoronary BMSC transfer thereafter. RESULTS: A total of 7 trials with 660 patients were available for analysis. Compared to baseline level, BMSC transfer at 4 to 7 days post-AMI significantly improved left ventricular ejection fraction (LVEF; 4.63% increase, 95% confidence interval [CI]: 1.00%-8.26%, P = 0.01), reduced left ventricular (LV) end-systolic dimensions (95% CI: - 0.53 - 0.02, P = 0.03), decreased the incidences of revascularization (odds ratio [OR]: 0.60, 95% CI: 0.37-0.97, P = 0.04), decreased the cumulative clinical events of death or recurrent myocardial infarction (OR: 0.32, 95% CI: 0.11-0.95, P = 0.04), and decreased culprit artery restenosis or ventricular arrhythmia (OR: 0.59, 95% CI: 0.36-0.96, P = 0.03) however these improvements did not reach statistical significance in emergent transfer trials (within 24 hour post-AMI). Compared with emergent transfer, intracoronary BMSC therapy at 4 to 7 days also significantly reduced the incidence of revascularization (P for interaction = 0.02). CONCLUSIONS: BMSC transfer at 4 to 7 days post-AMI was superior to that within 24 hours in improving LVEF, decreasing LV end-systolic dimensions, and reducing the incidence of revascularization.
Shuning Zhang; Aijun Sun; Danling Xu; Kang Yao; Zheyong Huang; Huan Jin; Keqiang Wang; Yunzeng Zou; Junbo Ge
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Clinical cardiology     Volume:  32     ISSN:  1932-8737     ISO Abbreviation:  -     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-08-24     Completed Date:  2009-10-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7903272     Medline TA:  Clin Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  458-66     Citation Subset:  IM    
Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary* / adverse effects,  mortality
Arrhythmias, Cardiac / etiology
Bone Marrow Transplantation* / adverse effects,  mortality
Combined Modality Therapy
Coronary Restenosis / etiology
Logistic Models
Middle Aged
Myocardial Infarction / mortality,  physiopathology,  surgery,  therapy*
Odds Ratio
Publication Bias
Randomized Controlled Trials as Topic
Recovery of Function
Reproducibility of Results
Risk Assessment
Stroke Volume
Thrombosis / etiology
Time Factors
Transplantation, Autologous
Treatment Outcome
Ventricular Function, Left

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Long-term prognosis of non-interventionally followed patients with isolated myocardial bridge and se...
Next Document:  The long-term risk of stroke in patients with acute myocardial infarction complicated with new-onset...